Compare BOTJ & ONCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BOTJ | ONCY |
|---|---|---|
| Founded | 1998 | 1998 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Major Banks | Pharmaceuticals and Biotechnology |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 95.9M | 94.0M |
| IPO Year | 2015 | 2002 |
| Metric | BOTJ | ONCY |
|---|---|---|
| Price | $22.00 | $1.06 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $7.33 |
| AVG Volume (30 Days) | 6.1K | ★ 841.0K |
| Earning Date | 04-30-2026 | 05-13-2026 |
| Dividend Yield | ★ 1.99% | N/A |
| EPS Growth | ★ 13.71 | N/A |
| EPS | ★ 1.99 | N/A |
| Revenue | ★ $4,273,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $2,505.00 |
| P/E Ratio | $11.12 | ★ N/A |
| Revenue Growth | ★ 6.74 | N/A |
| 52 Week Low | $13.03 | $0.33 |
| 52 Week High | $23.00 | $1.51 |
| Indicator | BOTJ | ONCY |
|---|---|---|
| Relative Strength Index (RSI) | 62.15 | 57.99 |
| Support Level | $20.18 | $0.94 |
| Resistance Level | N/A | $1.13 |
| Average True Range (ATR) | 0.57 | 0.09 |
| MACD | 0.09 | 0.02 |
| Stochastic Oscillator | 66.04 | 87.50 |
Bank of the James Financial Group Inc is a bank holding company that provides retail and commercial banking, deposit services, lending services, mortgage brokerage services, and other banking services. The company provides a range of deposit services including checking accounts, savings accounts and other time deposits of various types, ranging from daily money market accounts to longer-term certificates of deposit. It offers various types of secured and unsecured consumer loans, including personal loans, lines of credit, overdraft lines of credit, automobile loans, installment loans, demand loans, and home equity loans. It operates three business segments community banking; mortgage banking, and investment advisory services.
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer among others.